| 33.59 -0.44 (-1.29%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.1 |
1-year : | 48.01 |
| Resists | First : | 35.19 |
Second : | 41.1 |
| Pivot price | 32.38  |
|||
| Supports | First : | 31.33 |
Second : | 28.95 |
| MAs | MA(5) : | 33.83 |
MA(20) : | 32.37 |
| MA(100) : | 36.19 |
MA(250) : | 37.2 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 77.1 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 45.97 | Low : | 28.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VCEL ] has closed below upper band by 28.1%. Bollinger Bands are 8.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.06 - 34.22 | 34.22 - 34.39 |
| Low: | 32.51 - 32.71 | 32.71 - 32.92 |
| Close: | 33.2 - 33.53 | 33.53 - 33.86 |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Mon, 06 Apr 2026
Why Vericel (VCEL) Is Up 11.8% After Landing Long-Term BARDA Deal For NexoBrid - simplywall.st
Mon, 06 Apr 2026
Vericel (VCEL) CMO sells 3,472 shares after option exercise under 10b5-1 plan - Stock Titan
Sat, 04 Apr 2026
Assessing Vericel (VCEL) Valuation After Winning A US$196.87 Million Government Contract - Sahm
Fri, 03 Apr 2026
Vericel Corporation (VCEL) Stock Forecasts - Yahoo Finance
Thu, 02 Apr 2026
Vericel secures $197M BARDA deal, boosting NexoBrid supply plans - MSN
Tue, 31 Mar 2026
VCEL SEC Filings - Vericel 10-K, 10-Q, 8-K Forms - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 107.4 (%) |
| Shares Short | 5,040 (K) |
| Shares Short P.Month | 4,800 (K) |
| EPS | 0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.01 |
| Profit Margin | 5.9 % |
| Operating Margin | 24.1 % |
| Return on Assets (ttm) | 1.5 % |
| Return on Equity (ttm) | 5.1 % |
| Qtrly Rev. Growth | 23.2 % |
| Gross Profit (p.s.) | 4.03 |
| Sales Per Share | 5.42 |
| EBITDA (p.s.) | 0.44 |
| Qtrly Earnings Growth | 18.8 % |
| Operating Cash Flow | 52 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | 104.96 |
| PEG Ratio | 0 |
| Price to Book value | 4.79 |
| Price to Sales | 6.19 |
| Price to Cash Flow | 32.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|